Trial · NCT04697810
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 17 of 17
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Non-Alcoholic Fatty Liver Disease (NAFLD) activity score (NAS) | 36 weeks | Proportion of subjects who achieve a ≥2-point improvement in the non-alcoholic fatty liver disease (NAFLD) activity score (NAS) of the Non-Alcoholic Steatohepatitis Clinical Research Network (NASH CRN) |
| Primary | Adverse events (AEs) | 36 weeks | Incidence of AEs |
| Secondary | Alanine transaminase (ALT) mean | 36 weeks | Mean percent change from Baseline in serum ALT level |
| Secondary | Steady-state blood level of namodenoson | 36 weeks | Plasma trough concentration (ng/mL) of namodenoson taken at pre-dose samples |
| Other | ALT absolute | 36 weeks | Absolute change from Baseline in serum ALT |
| Other | ALT threshold | 36 weeks | Proportion of subjects who achieve ≥17-point reduction from Baseline in serum ALT |
| Other | Weight | 36 weeks | Change from Baseline in body weight |
| Other | Adiponectin | 36 weeks | Change from Baseline in serum adiponectin level |
| Other | Released N-terminal pro-peptide of type III collagen neoepitope (Pro-C3) | 36 weeks | Change from Baseline in Pro-C3 |
| Other | Serum Enhanced Liver Fibrosis (ELF) Score | 36 weeks | Change from Baseline in ELF Score, which is a continuous scale starting at zero, with higher scores indicating more severe disease |
| Other | FibroScan controlled attenuation parameter (CAP) | 36 weeks | Change from Baseline in CAP |
| Other | FibroScan-AST (FAST) Score | 36 weeks | Change from Baseline in FAST Score, which is a decimal score from 0 to 1, with higher scores indicating more severe disease |
| Other | Aspartate transaminase (AST) | 36 weeks | Change from Baseline in serum AST |
| Other | Gamma-glutamyl transferase (GGT) | 36 weeks | Change from Baseline in serum GGT |
| Other | Fibrosis-4 (Fib-4) Index | 36 weeks | Change from Baseline in Fib-4 Index |
| Other | NASH resolution | 36 weeks | Proportion of subjects who achieve histologic NASH resolution as defined by a ballooning score of 0 and an inflammation score of 0-1 without worsening of fibrosis |
| Other | NASH fibrosis improvement | 36 weeks | Proportion of subjects who achieve histologic NASH improvement by at least 1 point without worsening of NASH |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04697810/registered